Browse the corpus

Glycogen storage disease type II, or Pompe disease, is a rare inherited disorder caused by a deficiency of the enzyme acid α-glucosidase (GAA). This deficiency leads to impaired glycogen breakdown within lysosomes, primarily affecting muscular tissue. The disease is inherited in an autosomal recessive pattern and presents in 2 main phenotypes: infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD). IOPD is the more severe form, manifesting within the first months of life with hypotonia, hypertrophic cardiomyopathy, respiratory failure, and developmental delays, often leading to early mortality without treatment. LOPD, which emerges in childhood or adulthood, progresses more slowly, with symptoms such as proximal muscle weakness and respiratory insufficiency due to diaphragm involvement, while cardiac issues are rare. Diagnosis relies on detecting reduced GAA enzyme activity, genetic testing, and assessing cross-reactive immunologic material status. Early detection, particularly via newborn screening, and timely treatment initiation are critical to improving outcomes. This activity for healthcare professionals is designed to enhance the learner's competence in recognizing the clinical features of glycogen storage disease type II, performing the recommended evaluation, and implementing an appropriate interprofessional management approach to improve patient outcomes. Objectives: Identify the etiology of glycogen storage disease type II. Evaluate the diagnosis strategies of glycogen storage disease type II. Assess the management approaches for glycogen storage disease type II. Apply interprofessional team strategies to improve care coordination and outcomes for patients affected by glycogen storage disease type II. Access free multiple choice questions on this topic.

Glycogen storage disease type II, also known as Pompe disease, is a rare and progressive neuromuscular disorder inherited in an autosomal recessive manner. This disease results from a deficiency of the enzyme acid α-glucosidase (GAA), causing impairment in the degradation of glycogen within the lysosomes of the muscular tissue.[1][2] The clinical presentation of glycogen storage disease type II varies widely depending on the age of symptom onset, the degree of GAA deficiency, and the specific mutations involved.[3] Two phenotypes are described: infantile-onset Pompe disease (IOPD), which is the classic and more severe form, and late-onset Pompe disease (LOPD), which may manifest later in childhood or adulthood. IOPD typically presents within the first few months of life with severe symptoms, eg, hypotonia, hypertrophic cardiomyopathy, and respiratory failure; this last symptom remains the leading cause of mortality.[4] LOPD presents more insidiously, often with proximal muscle weakness and eventual respiratory insufficiency due to diaphragm involvement, while cardiac and gastrointestinal symptoms are rare.[5] Pompe disease diagnosis is confirmed through genetic testing, identifying pathogenic mutations in the GAA gene, and enabling the cross-reactive immunologic material (CRIM) status determination. CRIM status is crucial for assessing residual GAA protein production and is strongly associated with prognosis and response to enzyme replacement therapy.[6][7][8] Early detection and treatment, particularly in newborns, significantly alter the disease course, with enzyme replacement therapy (ERT) remaining the cornerstone of management.[9]

Glycogen storage disease type II is an autosomal recessive condition resulting from pathogenic variants in both copies of the GAA gene. This gene is located on the long arm of chromosome 17 (17q25.2-q25.3) and encodes for the GAA enzyme, which is responsible for catalyzing the breakdown of glycogen in lysosomes through α-1,4 and α-1,6 linkages (see Image. Glycogen, Free Glucose Release, and Glycogen Storage Diseases).[10][11] Mutations in the GAA gene lead to the production of unstable mRNA, which impacts several processes, including protein synthesis, posttranslational modifications, lysosomal trafficking, and the proteolytic function of the GAA enzyme.[12]

Glycogen storage disease type II incidence varies widely, with certain populations showing notably higher rates. For example, in French Guiana, the incidence is approximately 1 in 2,000 people, followed by Taiwan at about 1 in 15,000 people, both of which reflect data from national newborn screening (NBS) programs.[13][14] In Austria and the United States, where NBS strategies have also been implemented, the combined incidence of early and late-onset forms is estimated at 1 in 8,686 and 1 in 21,979 people, respectively.[15][16] In the Netherlands, screening of newborn blood spots indicated an incidence of GAA deficiency at around 1 in 40,000.[17] In countries without NBS, the incidence may be underestimated, as undiagnosed cases remain uncounted.

Pompe disease is driven by lysosomal glycogen accumulation due to GAA enzyme deficiency, leading to lysosomal rupture and the release of glycogen and other toxic materials into the cytoplasm. This cascade of reactions disrupts muscle architecture and causes progressive myofiber damage, with some fibers showing severe abnormalities while others remain unaffected.[18] Another important aspect of the disease is the accumulation of autophagic debris which results from excessive autophagosome formation combined with impaired fusion of these vesicles with lysosomes. This failure in lysosomal degradation leads to the buildup of undigested cellular components, contributing to oxidative stress, mitochondrial dysfunction, and further disruption of muscle fiber integrity.[19][20] Additionally, disruptions in cellular signaling pathways, including the AMPK and mTORC1 pathways, further impact muscle function. AMPK activation reflects an energy-deficient state, while reduced mTORC1 activity affects protein synthesis and muscle maintenance.[21][22]

The clinical presentation of glycogen storage disease type II varies widely and is influenced by the age at which symptoms appear. The degree of clinical severity, the extent of tissue damage, and the timing of onset are closely related to the specific mutations involved and the remaining GAA enzymatic activity.[3] The glycogen storage disease type II phenotypes that have been described are IOPD, the classic and more severe type, and LOPD, which can manifest in both childhood and adulthood. Infantile-Onset Pompe Disease Clinical Features IOPD usually presents at birth or within the first few months of life.[4] Common problems are hypotonia and muscle weakness with subsequent motor delay (96%), cardiomegaly (92%, commonly hypertrophic cardiomyopathy)[1], hepatomegaly (90%), macroglossia (62%), poor feeding and failure to thrive (53% to 57%); respiratory infections or dyspnea lead to respiratory failure, which is the most common cause of death in this population.[23] The electrocardiogram may show a short PR interval with wide QRS complexes in all leads. High-amplitude QRS complexes result from biventricular hypertrophy. The disease has also been associated with hearing loss. Late-Onset Pompe Disease Clinical Features LOPD patients often show symptoms that emerge in childhood or later and frequently present with musculoskeletal complications. Proximal muscle weakness, particularly in the lower limbs, is reported in about 58.7% of cases at diagnosis. Symptom progression is slower, but ultimately, respiratory failure may occur due to diaphragm involvement.[24] Cardiac or gastrointestinal symptoms are uncommon; however, some adults may develop arterial complications. A history of "clumsiness" while performing physical activities would be a clue for diagnosing this illness in adolescents or adults.

Pompe disease diagnosis is primarily based on enzymatic and genetic testing, with additional diagnostic tools used to support the findings. Early detection is critical, especially in newborns, as the absence of treatment can lead to death within the first year of life.[25] Acid α-Glucosidase Enzyme Activity The cornerstone of glycogen storage disease type II diagnosis is the measurement of lysosomal GAA enzyme activity.[26][27][28] Modern diagnostic protocols favor minimally invasive methods to detect GAA activity, eg, testing in dried blood spot (DBS) samples or leucocytes in liquid blood.[29] These assays are sensitive and reliable, though they can be complicated by interference from maltase glucoamylase, another enzyme active at acidic pH that may mask GAA deficiency. To overcome this challenge, inhibitors (eg, acarbose selectively) inhibit maltase glucoamylase, enhancing the specificity of the GAA test.[30] Abnormal enzyme activity detected in blood samples requires confirmation through additional testing, either by measuring enzyme activity in a different tissue type (eg, skin fibroblasts or muscle) or by conducting molecular genetic testing.[31][32] Genetic Analysis Genetic analysis is crucial to confirm glycogen storage disease type II diagnosis and identify pathogenic mutations in the GAA gene. Over 500 described mutations in the GAA gene have been identified, with some common variants associated with specific disease phenotypes. For example, the c.-32-13T>G splice mutation is the most common variant in patients with LOPD, with an allele frequency ranging from 40% to 70%.[33][34] Genetic testing can also help determine the CRIM status, indicating the amount of residual endogenous GAA production in patients with infantile-onset Pompe disease. This information is important as it can influence both the prognosis and the response to ERT. The CRIM-positive group has detectable GAA protein and typically shows a better response to treatment, while CRIM-negative patients lack detectable GAA protein and tend to have a worse prognosis.[6][7][8] Unspecific and Supportive Tests

Genetic testing can also help determine the CRIM status, indicating the amount of residual endogenous GAA production in patients with infantile-onset Pompe disease. This information is important as it can influence both the prognosis and the response to ERT. The CRIM-positive group has detectable GAA protein and typically shows a better response to treatment, while CRIM-negative patients lack detectable GAA protein and tend to have a worse prognosis.[6][7][8] Unspecific and Supportive Tests In addition to GAA enzyme activity and genetic analysis, several unspecific laboratory tests can provide supportive information. For example, elevated levels of serum creatine kinase (CK), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) may be observed in some glycogen storage disease type II patients, although these markers can also be normal.[35] Another potential biomarker for glycogen storage diseases is urinary excretion of tetrasaccharide 6-α-D-glucopyranosyl-maltotriose, which is increased in IOPD and other various conditions associated with glycogen turnover and, therefore, unspecific.[36] Histological findings, eg, the presence of periodic acid-Schiff-positive vacuolated lymphocytes and positive staining with acid phosphatase in a muscle biopsy observed under light microscopy, can also support a glycogen storage disease type II diagnosis.[32]

Treatment of Infantile-Onset Pompe Disease The development of ERT with alglucosidase alfa marked a significant advancement for IOPD patients, significantly improving survival, ventilator-free life, and cardiac health.[9][37] Initial clinical studies showed that alglucosidase alfa was effective in extending life expectancy and reducing the need for mechanical ventilation, especially when administered at 20 mg/kg every 2 weeks, which was well-tolerated.[38][39] Higher doses (eg, 40 mg/kg) demonstrated even better motor outcomes and ventilator-free survival in studies, although adverse effects were slightly more frequent, highlighting the importance of optimizing dosing for each patient.[38][40][39] Early initiation of ERT is crucial for maximizing outcomes, as delaying treatment past the first few months of life is associated with a less favorable prognosis.[41][42] In a pilot NBS program, early detection through dried blood spot testing allowed for the initiation of ERT within days of diagnosis, leading to improved survival and motor function among infants compared to untreated historical controls.[37] Furthermore, CRIM-negative patients, who are prone to immune reactions due to a lack of residual endogenous GAA production, benefit from immunomodulation combined with ERT to prevent adverse immunologic responses that could otherwise diminish treatment efficacy.[6] Treatment of Late-Onset Pompe Disease ERT with alglucosidase alfa has also been shown to improve motor and respiratory functions in LOPD patients, albeit with varying degrees of response based on the timing of treatment initiation and individual patient factors.[43] A phase 3 study demonstrated that ERT improved exercise capacity and respiratory function, as measured by the 6-minute walk test and forced vital capacity.[44] However, studies have indicated that while ERT initially improves motor and respiratory functions, the benefits may plateau after a few years, emphasizing the need for ongoing monitoring to assess disease progression and adjust the treatment regimen as necessary.[43][45]

ERT with alglucosidase alfa has also been shown to improve motor and respiratory functions in LOPD patients, albeit with varying degrees of response based on the timing of treatment initiation and individual patient factors.[43] A phase 3 study demonstrated that ERT improved exercise capacity and respiratory function, as measured by the 6-minute walk test and forced vital capacity.[44] However, studies have indicated that while ERT initially improves motor and respiratory functions, the benefits may plateau after a few years, emphasizing the need for ongoing monitoring to assess disease progression and adjust the treatment regimen as necessary.[43][45] Avalglucosidase alfa, a newer form of ERT, has shown potential as an alternative, with studies suggesting improved uptake in skeletal muscle due to modifications that increase affinity for muscle receptors. The COMET trial demonstrated comparable efficacy between avalglucosidase and alglucosidase in respiratory outcomes, although it did not achieve statistical superiority.[46] This variant received approval for LOPD treatment in 2021, with dosing based on body weight.[47] Emerging Therapeutic Approaches Beyond ERT, additional therapeutic strategies are being explored to enhance efficacy and reduce side effects: Pharmacological chaperone therapy: Chaperone therapy uses small molecules to stabilize the GAA enzyme, increasing cell activity. Studies show that combining ERT with chaperones (eg, miglustat) can boost and extend GAA activity, though further clinical data is needed to confirm these benefits.[48][49] Gene therapy: Gene therapy aims to deliver a functional GAA gene using viral vectors like AAV and lentivirus and seeks to address ERT limitations. Preclinical and initial studies in animal models and small patient groups show encouraging results for reducing glycogen accumulation, especially in cardiac and skeletal muscle, although issues like toxicity and immune response remain challenging.[50][51] Substrate reduction therapy: Another experimental strategy is inhibiting glycogen synthesis to limit its buildup in tissues. Glycogen synthase antagonists and antisense oligonucleotides targeting the Gys1 gene are being tested in animal models, showing initial positive effects.[52][53]

The differential diagnosis for IOPD includes: Spinal muscular atrophy 1: Differs from IOPD because no cardiac muscle is involved Danon disease: Differs from IOPD because inheritance is X-linked [54] The differential diagnosis for LOPD includes: Limb-girdle muscular dystrophy: Differs from LOPD because axial muscles are not affected Duchenne-Becker muscular dystrophy: Differs from LOPD because inheritance is X-linked Other glycogen storage disorders: May be considered; mainly differentiated by a lack of hypoglycemia in glycogen storage disease type II (see Image. Glycogen Storage Disease Types)

Prognosis and Long-Term Considerations The prognosis for IOPD patients has improved significantly with ERT, but long-term survivors often experience progressive symptoms that ERT does not entirely prevent. These include cognitive impairments due to glycogen buildup in the brain, as well as sensorineural hearing loss.[55][56][57] For LOPD patients, while ERT slows progression, some patients eventually require ventilatory support or become wheelchair-dependent, underscoring the need for improved and timely therapies.[58][45] In response, ongoing research is exploring next-generation treatments, including improved ERT options such as cipaglucosidase (a novel recombinant human acid α-glucosidase) combined with miglustat (an enzyme stabilizer) for LOPD, as well as experimental gene therapy strategies aimed at overcoming current ERT limitations.[49][59] Further studies are needed to confirm the effectiveness of these therapies and provide insights into optimal long-term management for both IOPD and LOPD.

Complications of Pompe Disease Pompe disease, in both IOPD and LOPD forms, presents a wide range of complications, particularly respiratory, due to progressive muscle weakness.[60] Immune responses to treatment, especially in CRIM-negative patients, are also well-known complications.[61] Respiratory complications include diaphragm weakness, reduced cough strength, and impaired airway clearance, ultimately leading to recurrent respiratory infections and aspiration pneumonia.[62][63] Sleep-disordered breathing, such as obstructive sleep apnea and nocturnal hypoventilation, are common and contribute to reduced sleep quality, morning headaches, and excessive daytime sleepiness.[64] In IOPD, even with early initiation of ERT, airway abnormalities such as tracheobronchomalacia and macroglossia persist, potentially exacerbating respiratory failure.[65] Furthermore, additional interventions such as noninvasive ventilation and advanced airway clearance techniques are important aspects of patient management.[66] Adverse effects related to ERT itself include mild to moderate infusion-related reactions, as well as severe outcomes such as anaphylaxis and immune-mediated respiratory decline in some CRIM-negative patients.[44]

Managing late-onset glycogen storage disease type II disease requires a collaborative, interprofessional approach by key consultants to address its diverse and progressive manifestations. Key specialists include: Neurologist: Neurologists oversee the progression of proximal muscle weakness and coordinate comprehensive care plans. They monitor the effects of ERT on muscle strength and guide the management of neuromuscular complications, including fine and gross motor impairments.[54] Pulmonologist: Pulmonologists are critical in managing respiratory complications, including diaphragm weakness and sleep-disordered breathing. Regular pulmonary function assessments, eg, forced vital capacity in upright and supine positions, are essential to monitoring disease progression.[54][67] Pulmonologists also guide the initiation of noninvasive ventilation for patients with nocturnal hypoventilation or significant respiratory muscle weakness.[68] Physical therapist: Physical therapists design individualized exercise programs to preserve motor function, prevent contractures, and address musculoskeletal impairments. Therapeutic exercise should begin with mild to moderate aerobic activity and progress gradually, closely monitoring heart rate, oxygen saturation, and perceived exertion.[54][69] Physical therapists also guide the use of adaptive equipment, eg, walkers or ankle–foot orthoses, and educate patients on home-based exercise programs.[54][70] Additional specialists may include: An interprofessional team may also involve orthopedic specialists to address scoliosis, contractures, and limb deformities, occupational therapists to improve daily living activities and suggest adaptive equipment, and endocrinologists to oversee osteoporosis management and bone health.[71][72] Dietitians optimize nutrition and manage feeding difficulties, while speech therapists provide support for swallowing difficulties. Social workers and genetic counselors address psychosocial needs and family considerations.[54]

Educating caregivers and clinicians is crucial in improving outcomes for Pompe disease by promoting early detection and adherence to treatment protocols. Newborn screening plays a vital role in identifying IOPD before symptoms develop, allowing for the timely initiation of enzyme replacement therapy, significantly improving survival, and reducing the need for mechanical ventilation. Additionally, reinforcing the necessity of adherence to ERT, routine monitoring for disease progression, and the use of supportive therapies, such as physical and respiratory therapy, are essential steps for optimizing long-term outcomes and reducing complications.

Newborn Screening NBS for Pompe disease is essential for early diagnosis and timely treatment, especially for IOPD, where early initiation of enzyme replacement therapy significantly improves survival and reduces the need for mechanical ventilation.[37] In several countries, including Taiwan, Japan, and some states in the United States, NBS is widely implemented, utilizing dried blood spots to measure α-glucosidase enzyme activity through fluorometry, tandem mass spectrometry, or digital microfluidic fluorometry.[73][74][75] According to Prosser et al, implementing NBS for 4 million infants annually in the United States could detect approximately 134 cases of glycogen storage disease type II, including 40 cases of IOPD, compared to only 36 cases identified through clinical presentation alone. NBS would also uncover 94 cases of LOPD, many of which might remain asymptomatic for years or even decades. Screening for IOPD specifically could help prevent 13 deaths and identify 26 children at risk of requiring mechanical ventilation by the age of 36 months.[76] To confirm the diagnoses, GAA is crucial, particularly for IOPD cases where specific mutations are associated with severe clinical manifestations.[77] In the United States, including Pompe disease screening in the Recommended Uniform Screening Panel (RUSP) in 2015 marked a milestone, enabling the early identification of IOPD and LOPD cases before symptom onset, which can significantly improve outcomes.[37][76] Despite advancements, challenges remain in standardizing enzyme activity cutoff values and reducing false-positive results.[78]

The management of glycogen storage disease type II, a rare and progressive lysosomal storage disorder, requires an interprofessional approach to optimize patient-centered care, improve outcomes, and enhance team performance. Early diagnosis and treatment are critical, particularly for IOPD, where delayed ERT significantly worsens prognosis. LOPD also demands coordinated care to address progressive musculoskeletal and respiratory complications. Healthcare professionals must possess the clinical skills to identify Pompe disease early, interpret enzymatic and genetic testing results, and initiate evidence-based interventions. The interprofessional team collaborates to implement individualized care plans tailored to each patient’s unique needs. This includes using ERT, managing immune responses in CRIM-negative patients, and supportive therapies like physical and respiratory therapy. Effective interprofessional communication is essential in ensuring seamless coordination across disciplines. Each team member, including physicians, nurses, advanced practitioners, pharmacists, and allied health professionals, contributes their expertise to streamline the diagnostic and therapeutic process. Care coordination minimizes delays in treatment, reduces complications, and enhances patient safety.